Skip to main content
Erschienen in: Virchows Archiv 5/2023

27.07.2023 | ORIGINAL ARTICLE

Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer

verfasst von: Mònica Gonzàlez-Farré, Joan Gibert, Pablo Santiago-Díaz, Jordina Santos, Pilar García, Jordi Massó, Beatriz Bellosillo, Belén Lloveras, Joan Albanell, Ivonne Vázquez, Laura Comerma

Erschienen in: Virchows Archiv | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Stromal tumour infiltrating lymphocytes (sTIL) in haematoxylin and eosin (H&E) stained sections has been linked to better outcomes and better responses to neoadjuvant therapy in triple-negative and HER2-positive breast cancer (TNBC and HER2 +). However, the infiltrate includes different cell populations that have specific roles in the tumour immune microenvironment. Various studies have found high concordance between sTIL visual quantification and computational assessment, but specific data on the individual prognostic impact of plasma cells or lymphocytes within sTIL on patient prognosis is still unknown. In this study, we validated a deep-learning breast cancer sTIL scoring model (smsTIL) based on the segmentation of tumour cells, benign ductal cells, lymphocytes, plasma cells, necrosis, and ‘other’ cells in whole slide images (WSI). Focusing on HER2 + and TNBC patient samples, we assessed the concordance between sTIL visual scoring and the smsTIL in 130 WSI. Furthermore, we analysed 175 WSI to correlate smsTIL with clinical data and patient outcomes. We found a high correlation between sTIL values scored visually and semi-automatically (R = 0.76; P = 2.2e-16). Patients with higher smsTIL had better overall survival (OS) in TNBC (P = 0.0021). In the TNBC cohort, smsTIL was as an independent prognostic factor for OS. As part of this work, we introduce a new segmentation dataset of H&E-stained WSI.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Loi S et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol 31(7):860–867. https://doi.org/10.1200/JCO.2011.41.0902CrossRefPubMed Loi S et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol 31(7):860–867. https://​doi.​org/​10.​1200/​JCO.​2011.​41.​0902CrossRefPubMed
8.
Zurück zum Zitat Sarah Dudgeon AN, Wen S, Gallas BD A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study Title A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study Affiliations of Authors. iRhythm Technologies Inc Sarah Dudgeon AN, Wen S, Gallas BD A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study Title A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study Affiliations of Authors. iRhythm Technologies Inc
23.
Zurück zum Zitat Moncusí A, Villanueva X, Noguera A, Bonilla M, Posso M, Macià F (2022) Informe 2022 del Registre de Tumors de l’Hospital del Mar (RTHMar), Barcelona. Barcelona: Parc de Salut MAR; 2022. Barcelonas Moncusí A, Villanueva X, Noguera A, Bonilla M, Posso M, Macià F (2022) Informe 2022 del Registre de Tumors de l’Hospital del Mar (RTHMar), Barcelona. Barcelona: Parc de Salut MAR; 2022. Barcelonas
25.
Zurück zum Zitat Wolff AC et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol 36:2105–2122. https://doi.org/10.1200/JCO Wolff AC et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol 36:2105–2122. https://​doi.​org/​10.​1200/​JCO
29.
Zurück zum Zitat Hendry S et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24(6):311–335. https://doi.org/10.1097/PAP.0000000000000161. (Lippincott Williams and Wilkins)CrossRefPubMedPubMedCentral Hendry S et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24(6):311–335. https://​doi.​org/​10.​1097/​PAP.​0000000000000161​. (Lippincott Williams and Wilkins)CrossRefPubMedPubMedCentral
Metadaten
Titel
Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer
verfasst von
Mònica Gonzàlez-Farré
Joan Gibert
Pablo Santiago-Díaz
Jordina Santos
Pilar García
Jordi Massó
Beatriz Bellosillo
Belén Lloveras
Joan Albanell
Ivonne Vázquez
Laura Comerma
Publikationsdatum
27.07.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 5/2023
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-023-03608-4

Weitere Artikel der Ausgabe 5/2023

Virchows Archiv 5/2023 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …